Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

NOV 18 2004

Docket Number 546322000321	Application Number 09/646,807
Applicant: Michael Wayne GRAHAM and Robert Norman RICE	
Filing Date December 5, 2000	Group Art Unit ~~1636~~ 1633
Mailing Date November 16, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
BW	1.	03/02/1993	US 5,190,931	Inouye			
BW	2.	05/04/1993	US 5,208,149	Inouye			
BW	3.	12/21/1993	US 5,272,065	Inouye et al.			
BW	4.	09/04/2003	US 2003/0165894 A1	Waterhouse et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
BW	5.	02/01/2001	AU 729454	Australia				
	6.	06/14/1995	EP 0465572B1	EP				
	7.	11/12/1992	WO 92/19732	WO				
	8.	01/20/1994	WO 94/01550	WO				
	9.	08/31/1995	WO 95/23225	WO				
	10.	11/27/1997	WO 97/44460	WO				
	11.	11/26/1998	WO 98/53083	WO				
	12.	09/30/1999	WO 99/49029A1	WO				
	13.	12/02/1999	WO 99/61631	WO				
	14.	08/03/2000	WO 00/44895	WO				
	15.	08/03/2000	WO 00/44914	WO				
	16.	09/27/2001	WO 01/70949	WO				
	17.	03/20/2003	WO 03/022052	WO				
	18.	04/03/2003	WO 03/027298	WO				
BW	19.	07/10/2003	WO 03/056012	WO				

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

NOV 18 2004

Docket Number 546322000321	Application Number 09/646,807
Applicant: Michael Wayne GRAHAM and Robert Norman RICE	
Filing Date December 5, 2000	Group Art Unit 1636
Mailing Date November 16 2004	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
BW	20.	Agrawal et al. (2003) "RNA Interference: Biology, Mechanism, and Applications" Microb. Mol. Biol. Rev. 67:657-685.
	21.	Agrawal et al. (1995) "Self-Stabilized Oligonucleotides as Novel Antisense Agents" pp 105-120.
	22.	Bahramian et al. (1999) "Transcriptional and Posttranscriptional Silencing of Rodent α1(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene" Molecular and Cellular Biology 19 (1): 274-283.
	23.	Bhan et al. (1997) "2′,5′-Linked Oligo-3′-deoxyribonucleoside Phosphorothiate Chimeras: Thermal Stability and Antisense Inhibition of Gene Expression" Nucleic Acids Research 1 (16): 3310-3317.
	24.	Boldin et al. (1996) "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" Cell 85: 803-815.
	25.	Borecky et al. (1981-1982) "Therapeutic Use of Double-Stranded RNAs in Man" Tex Rep Biol Med 14: 575-581.
	26.	Braich et al. (1997) Regiospecific Solid-Phase Synthesis of Branched Oligonucleotides Effect of Vicinal 2′,5′- (or 2′,3′-) and 3′,5′-Phosphodiester Linkages on the Formation of Hairpin DNA" Bioconjugate Chem 8: 370-377.
	27.	Carthew (2001) "Gene Silencing By Double-Stranded RNA" Curr. Op. Cell. Biol. 13: 244-248.
	28.	Cohli et al. (1994) "Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s)" Antisense Research and Development 4: 19-26.
	29.	Couzin (2002) "Small RNAs Make Big Splash" Science 298: 2296-2297.
	30.	Czauderna (2003) "Structural Variations and Stabiling Modifications of Synthetic siRNAs in Mammalian Cells" Nucleic Acids Research 31 (11): 1-12.
	31.	Doench et al. (2003) "siRNA Can Function as miRNAs" Genes and Development 17:438-442.
	32.	Elbashir et al. (2001) Functional Anatomy of siRNAs for mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate" The EMBO Journal 20 (23): 6877-6888.
	33.	Elbashir et al. (2002) "Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs" Methods 26: 199-213.
	34.	Fire et al. (1991) "Production of Antisense RNA Leads to Effective and Specific Inhibition of Gene Expression in C. Elegans Muscle" Development 113(2): 503-514.
BW	35.	Flavell, R. B. (1994) "Inactivation of Gene Expression in Plants as a Consequence of Specific Sequence Duplication" Proc. Natl. Acad. Sci., 91:3490-3496.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 546322000321	Application Number 09/646,807
INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Applicant: Michael Wayne GRAHAM and Robert Norman RICE	
	Filing Date December 5, 2000	Group Art Unit 1636
	Mailing Date November 16, 2004	

NOV 18 2004

BW	36.	Fraser et al. (1996) "Effects of c-myc first exons and 5' synthetic hairpins on RNA translation in oocytes and early embryos of Xenopus laevis" Oncogene 12(6):1223-30.
	37.	Giordano et al. (2000) "RNAi Triggered By Symmetrically Transcribed Transgenes in Drosophila Melanogaster" Genetics 160:637-648.
	38.	Goff et al. (1997) "Analysis of Hoxd-13 and Hoxd-11 Misexpression in Chick Limb Buds Reveals that Hox Genes Affect Both Bone Condensation and Growth" Development 124: 627-636.
	39.	Grasby et al. (Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA" Biochemistry 34: 4068-4076.
	40.	Griffey (1996) 2'O-Aminopropyl Ribonucleotides: A Zwitterrionic Modification That Enhances The Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides" J. Med. Chem 39: 5100-5109.
	41.	Gryaznov, Sergei M. and Robert L. Letsinger (1993) "Template Controlled Coupling and Recombination of Oligonucleotide Blocks Containing Thiophosphoryl Groups" Nucleic Acids Research 21 (6): 1403-1408.
	42.	Ha et al. (1996) "A Bilged lin-4/lin-14 RNA Duplex is Sufficient For Caenorhabditis Elegans lin-14 Temporal Gradient Formation" Gene and Development 10: 3041-3050.
	43.	Hannon (2002) "RNA Interference" Nature 418: 244-251.
BW	44.	Hoke et al. (1991) "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection", Nucleic Acids Research 19 (20): 5743-5748.
	45.	Hungarian Patent Office Search Report mailed July 13, 2004, for Hungary patent application no. P0101225, 1 page.
	46.	International Search Report mailed on May 10, 2001, for PCT patent application no. PCT/AU01/00297 filed March 16, 2001, 2 pages.
	47.	International Search Report mailed on November 14, 2002, for PCT patent application no. PCT/AU02/01326 filed September 27, 2002, 4 pages.
BW	48.	Jorgensen et al. (1999) "Do Unintended Antisense Transcripts Contribute To Sense Cosuppression in Plants" TIG 15:11-12.
	49.	Kennerdell et al. (2000) "Heritage Gene Silencing in Drosophila Using Double-Stranded RNA" Nature Biotechnology 18:896-898.
	50.	Kennerdell et al. (1998) "Use of dsRNA-Mediated Genetic Interference to Demonstrate that Frizzled and Frizzled 2 Act in the Wingless Pathway" Cell 95: 1017-1026.
	51.	Kibler et al. (1997) "Double Stranded RNA is a Trigger for Apoptosis in Vaccinia Virus Infected Cells" Journal of Virology 71(3): 1992-2003.
	52.	Kitabwalla et al. (2002) "RNA Interference--A New Weapon Against HIV and Beyond", N Engl J Med 347 (17): 1364-1367.
	53.	Klink et al. (2000) The Efficacy of RNAi in the Study of the Plant Cytoskeleton" J. Plant Growth Reg. 19: 371-384.
BW	54.	Kowolik (2001) "Locus Control Region of the Human CD2 Gene in a Lentivirus Vector Confers Position-Independent Transgene Expression" Journal of Virology 75 (10): 4641-4648.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 546322000321	Application Number 09/646,807
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Applicant: Michael Wayne GRAHAM and Robert Norman RICE	
	Filing Date December 5, 2000	Group Art Unit 1636
	Mailing Date November 16, 2004	

NOV 18 2004
PATENT & TRADEMARK OFFICE

BW	55.	Kowolik et al. (2002) "Preferential Transduction of Human Hepatocytes with Lentiviral Vectors Pseudotyped By Sendai Virus F Protein" Molecular Therapy 5 (6): 762-769.
	56.	Kozak (1989) "Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs" Mol. Cell. Biol. 9:5134-5142.
	57.	Kreutzer et al. "Specific Inhibition of Viral Gene Expression by Double-Stranded RNA *in Vitro*" Fall Meeting S169.
	58.	Kumar et al. (1998) "Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher Eukaryotes" Microbiology and Molecular Biology Reviews 62 (4): 1415-1434.
	59.	Li et al. (2000) "Double-Stranded RNA Injections Produces Null Phenotype in Zebrafish" Dev. Biol. 217(2):394-405. Erratum in: Dev. Biol. (2000) 220(2):432.
	60.	Liebhaber et al. (1992) "Translation inhibition by an mRNA coding region secondary structure is determined by its proximity to the AUG initiation codon" J. Mol. Biol. 226:609-621.
	61.	Lin et al. (1999) "Policing Rogue Genes" Nature 402: 128-129.
	62.	Lingelbach et al. (1988) "An extended RNA/RNA duplex structure within the coding region of mRNA does not block translational elongation" Nuc. Acids Res. 16 3405-3414.
	63.	Lipinski et al. (1997) "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings" Advanced Drug Delivery Reviews 23: 3-25.
	64.	Lisziewicz et al. (1991) "Tat-Regulated Production of Multimerized TAR RNA Inhibits HIV-1 Gene Expression" New Biologist 3:82-89.
	65.	Loomis et al. (1991) "Antisense RNA inhibition of expression of a pair of tandemly repeated genes results in a delay in cell-cell adhesion in Dictyostelium" Antisense Res. Dev.1:255-260.
	66.	Ma et al. (1993) "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach" Biochemistry 32: 1751-1758.
	67.	Majumdar et al. (1998) "Targeted Gene Knockout Mediated by Tripple Helix Forming Oligonucleotides" Nature Genetics 20: 212-214.
	68.	McManus et al. (2002) "Gene Silencing in Mammals By Small Interfering RNAs" Nat. Rev. Genet. 3 (10): 737-747.
	69.	Metzlaff et al. (1997) "RNA-Mediated RNA Degradation and Chalcone Synthase A Silencing in Petunia" Cell 88:845-854.
	70.	Mikoshiba et al. (1991) "Molecular biology of myelin basic protein: gene rearrangement and expression of anti-sense RNA in myelin-deficient mutants" Comp. Biochem. Physiol. 98:51-61.
	71.	Milhaud et al. (1991) "Free and Liposome-Encapsulated Double-Stranded RNAs as Inducers of Interferon, Interleukin-6, and Cellular Toxicity" Journal of Interferon Research 11: 261-265.
	72.	Montgomery et al. (1998) "Double-Stranded RNA as a Mediator in Sequence-Specific Genetic Silencing and Co-Suppression" TIG 14 (7): 255-258.
	73.	Montgomery et al. (1998) "RNA as a Target of Double-Stranded RNA-Mediated Genetic Interference in Caenorhabditis Elegans" Proc. Natl. Acad. Sci. 95: 15502-15507.
BW	74.	Moss et al. (1997) "The Cold Shock Domain Protein LIN-28 Controls Development Timing in C. Elegans and is Regulated by the lin-4 RNA" Cell 88: 637-646.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

NOV 1 8 2004

Docket Number 546322000321	Application Number 09/646,807
Applicant: Michael Wayne GRAHAM and Robert Norman RICE	
Filing Date December 5, 2000	Group Art Unit 1636
Mailing Date November 16, 2004	

BW		75.	Ngo et al. (1998) "Double-Stranded RNA Induces mRNA Degradation in Trypanosoma Brucei" Proc. Natl. Acad. Sci. 95: 14687-14692.
		76.	Nielsen et al. (1997) "A Novel Class of Conformation Restricted Oligonucleotide Analogues: Synthesis of 2',3'-Bridged Monomers and RNA-Selective Hybridisation" Chem. Commun.: 825-826.
		77.	Nikiforov et al. (1992) "Oligodeoxynucleotides Containing 4-thiothymidine and 6-thiodeoxyguanosine as affinity labels for the Eco RV Restriction Endonuclease and Modification Methylase" Nucleic Acids Research 20 (6): 1209-1214.
		78.	Okano et al. (1991) "Myelin basic protein gene and the function of antisense RNA in its repression in myelin-deficient mutant mouse" J. Neurochem. 56:560-567.
		79.	Paddison et al. (2002) "Short Hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells" Genes and Development 16: 948-958.
		80.	Pegram et al. (1998) Phase II study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185$^{HER2/neu}$ Monoclonal HER2/Neu-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment" Journal of Clinical Oncology 16 (8): 2659-2671.
		81.	Pelletier et al. (1985) "Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency" Cell, 40:515-526.
		82.	Peng et al. (2001) "Development of an MFG-Based Retroviral Vector System for Secretion of High Levels of Functionally Active Human BMP4" Molecular Therapy 4 (2): 95-104.
		83.	Piccin, et al. (2001) "Efficient and Heritable Functional Knock-out of an Adult Phenotype in Drosophila using a GAL4-Driven Hairpin RNA Incorporating a Heterologous Spacer" Nucleic Acids Research, 29(12) E55:1-5.
		84.	Plasterk et al. (2000) "The Silence of the Genes" Curr. Op. Gen. Dev. 10:562-567.
		85.	Que et al. (1997) "The Frequency and Degree of Cosuppression by Sense Chalcone Synthase Transgenes Are Dependent on Transgene Promoter Strength and Are Reduced by Premature Nonsense Codons in the Transgene Coding Sequence" Plant Cell 9: 1357-1368.
		86.	Regalado (2002). "Turning Off Genes Sheds New Light On How They Work" *The Wall Street Journal*: 4 pages.
		87.	Sarver et al. (1990) "Ribozymes as Potential Anti-HIV-1 Therapeutics Agents" Science 247:1222-1225.
		88.	Schaller (2003) "The Role of Sterols in Plant Growth and Development" Prog. Lipid Res. 42:163-175.
		89.	Schmidt (2004) "RNA Interference Detected 20 years ago" Nat. Biotechnol. 22: 267-268.
		90.	Schmidt et al. (1983) "Cycloheximide Induction of Aflatoxin Synthesis in a Nontoxigenic Strain of Aspergillus Flavus" Bio/Technology 1: 794-795.
		91.	Schmidt et al. (1986) "Viral Influences on Aflatoxin Formation by Aspergillus Flavus" Appl Microbiol. Biotechnol. 24: 248-252.
		92.	Schwartz et al. (2002) "Evidence that siRNAs Function as Guides, Not Primers in the Drosophila and Human RNAi Pathways" Molecular Cell 10: 537-548.
		93.	Sharp (1999) "RNAi and Double-Stranded RNA" Genes and Development 13(2): 139-141.
BW		94.	Shi et al. (1998) "A CBP/p300 Homolog Specifies Multiple Differentiation Pathways in Caenorhabditis Elegans" Genes and Development (12)7: 943.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

NOV 18 2004

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 546322000321	Application Number 09/646,807
Applicant: Michael Wayne GRAHAM and Robert Norman RICE	
Filing Date December 5, 2000	Group Art Unit 1636
Mailing Date November 16, 2004	

BW	95.	Sinha (1997) "2 Large-Scale Synthesis: Approaches to Large-Scale Synthesis of Oligodeoxynecleotides and their Analogs" Antisense From Technology to Therapy Lab Manual and Textbook 6: 30-58.
	96.	Skripkin et al. (1996) "Psoralen Crosslinking Between Human Immunodeficiency Virus Type 1 RNA and Primer $tRNA_3^{Lys}$" Nucleic Acids Research, Vol. 24, No: 3: 509-514.
	97.	Steinecke et al. (1992) "Expression of a Chimeric Ribozyme Gene Results in Endonucleolytic Cleavage of a Target mRNA and a Concomitant Reduction of Gene Expression in vivo" Nucleic Acids Res. 23:2259-2268.
	98.	Strauss (1999) "Candidate Gene Silencers' Found" Science 286: 886.
	99.	Sullenger et al. (1990) "Expression of Chimeric tRNA-Driven Antisense Transcripts Renders NIH 3T3 Cells Highly Resistant to Moloney Murine Leukemia Virus Replication" Mol. Cell. Biol. 10:6512-6523.
	100.	Sullenger et al. (1993) "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA" Science 262:1566-1569.
	101.	Svoboda, P. et al. (2001) "RNAi in Mouse Oocytes and Preimplantation Embryos: Effectiveness of Hairpin dsRNA" Biochem Biophys Res Commun. 287(5): 1099-1104.
	102.	Tijsterman et al. (2002) "The Genetics of RNA Silencing" Ann. Rev. Genet. 36:489-519.
	103.	Timmons et al. (1998) "Specific Interference by Ingested dsRNA" Nature 395: 854.
	104.	Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle" Chemical Reviews (9) 4: 544-584.
	105.	Watson (1988) "A new revision of the sequence of plasmid pBR322" Gene 70:399-403.
	106.	Weaver et al. (1981) "Introduction by molecular cloning of artifactual inverted sequences at the 5' terminus of the sense strand of bovine parathyroid hormone cDNA" PNAS 78: 4073-4077.
BW	107.	Wess et al. (2003) "Early Days for RNAi" BioCentury, Vol. 11, No. 12: A1-23.
	~~108.~~	~~Written Opinion mailed on April 17, 2004, for PCT application no PCT/US03/01177 filed September 9, 2003: 7 pages.~~
BW	109.	Yam et al. (2002) "Design of HIV Vectors for Efficient Gene Delivery into Human Hematopoietic Cells" Molecular Therapy 5 (4): 479-484.
BW	110.	Yamamoto et al. (1997) "Inhibition of Transcription by the TAR RNA of HIV-1 in a Nuclear Extract of HeLa Cells" Nucleic Acids Research 25 (17): 3445-3450.
BW	111.	Yee et al. (2001) "Prospects for Gene Therapy Using HIV-Based Vectors" Somatic Cell and Molecular Genetics, Vol. 26, Nos. 1/6:159-173.
BW	112.	Zhao et al. (1993) "Generating Loss-of-Function Phenotype of the Fushi Tarazu Gene with a Targeted Ribozyme in Drosophila" Nature 365:448-451.

EXAMINER: /Brian Whiteman/	DATE CONSIDERED: 06/20/2006

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

OIPE
FEB 11 2005
PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/646,807
Filing Date	December 5, 2000
First Named Inventor	Michael W. GRAHAM
Art Unit	~~1636~~ 1635
Examiner Name	~~D. Sullivan~~
Attorney Docket Number	546322000321

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BW	AA	US 4,766,072	08-23-1988	Jendrisak et al.	
	AB	US 2003/0056235 A1 with amendments	03-20-2003	Fire et al.	
	AC	US 2004/0064842 A1	04-01-2004	Graham et al.	
	AD	US 2004/0237145 A1	11-25-2004	Graham et al.	
	AE	US 2003/0159161 A1	08-21-2003	Graham et al.	
	AF	US 2004/0180439 A1	09-16-2004	Graham et al.	
~~BW~~	AG	US 2004/0266005 A1	12-30-2004	Graham et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
BW	BA	WO 97/44450	11-27-1997			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brian Whiteman/	Date Considered	06/20/2006

sf-1849676

OIPE JC59
FEB 25 2005
PATENT & TRADEMARK OFFICE

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete If Known	
Application Number	09/646,807
Filing Date	December 5, 2000
First Named Inventor	Michael W. GRAHAM
Art Unit	1636 1637
Examiner Name	~~D. Sullivan~~
Attorney Docket Number	546322000321

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BW	AA	US 5,578,716	11-26-1996	Szyf et al.	
BW	AB	US 5,998,383	12-07-1999	Wright et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
BW	BA	WO 95/15378	06-08-1995			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
BW	CA	Agrawal et al. (2000) "Antisense therapeutics: is it as simple as complementary base recognition?" Molecular Medicine Today 6: 72-81.	
	CB	Cameron et al. (1994) "Multiple Domains in a Ribozyme Construct Confer Increased Suppressive Activity in Monkey Cells" Antisense Research and Development 4: 87-94.	
	CC	Harborth et al. (2003) "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and SHort Hairpin RNAs and the Effect on Mammalian Gene Silencing" Antisense and Nucleic Acid Drug Development 13: 83-105.	
	CD	Holen et al. (2002) "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor" Nucleic Acids Research 30 (8): 1757-1766.	
	CE	Jen et al. (2000) "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies" Stem Cells 18: 307-319.	
	CF	McManus et al. (2002) "Gene Silencing using micro-RNA designed hairpins" RNA 8: 842-850.	
	CG	McManus et al. (2002) "Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes" Journal of Immunology 169: 5754-5760.	
	CH	Opalinska et al. (2002) "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications" Nature Reviews 1: 503-514.	
BW	CI	Randall et al. (2003) "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs" PNAS 100 (1): 235-240.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brian Whiteman/	Date Considered	06/20/2006

sf-1876554

ALTERNATIVE TO PTO/SB/08a/b (06-03)

OIPE JC#42
JUN 3 0 2005
PATENT & TRADEMARK OFFICE

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/646,807
				Filing Date	December 5, 2000
				First Named Inventor	Michael W. GRAHAM
(Use as many sheets as necessary)				Art Unit	~~1636~~ 1635
				Examiner Name	D. Sullivan
Sheet	1	of	1	Attorney Docket Number	546322000321

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
~~BW~~	1.	WO-99/09045	02-25-1999	Somagenics, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	2	~~European Search Report mailed June 3, 2005, for European patent~~ application no. 04015041, filed March 19, 1999, 4 pages	
BW	3.	BASS, Brenda L. (May 24, 2001) "RNA Interference: The Short Answer," Nature, 411:428-429	
BW	4.	HARBORTH, Jens et al. (2001) "Identification of Essential Genes in Cultured Mammalian Cells Using Small Interfering RNAs," Journal of Cell Science, 114:4557-4565	
BW	5.	MANCHE, Lisa et al. (Nov. 1992) "Interactions Between Double-Stranded RNA Regulators and the Protein Kinase DAI," Molecular and Cellular Biology, 12(11):5238-5248	
BW	6.	PADDISON, Patrick J. et al. (July 2002) "RNA Interference: The New Somatic Cell Genetics?" Cancer Cell, 2:17-23	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Brian Whiteman/	Date Considered	06/20/2006

sf-1956070

OIPE
JAN 25 2006
IAP84
PATENT & TRADEMARK OFFICE

PTO/SB/08a (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/646,807
Filing Date	December 5, 2000
First Named Inventor	Michael W. Graham
Art Unit	1635
Examiner Name	~~Sean McGarry~~ Whiteman
Attorney Docket Number	BENI/0022.P1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
BW	C1	Stam et al. (1997) "Post-transcriptional silencing of chalcone synthase in *Petunia* by inverted transgene repeats" The Plant Journal 12(1): 63-82	
~~BW~~	~~C2~~	~~Australian Written Opinion for SG200205122-5, dated October 24, 2005 (BENI/0022.OO)~~	

Examiner Signature	/Brian Whiteman/	Date Considered	06/20/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.